32 results about "Chronic phase chronic myelogenous leukemia" patented technology

Compounds of the present invention, alone and in combination with other active agents, find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to for example malignant melanomas, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).

The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

The present invention relates to new organic compound, and is especially the preparation process of N-(2-methyl-5-nitro) phenyl-4-(3-pyridyl) pyrimidiyl-2-amine as the key intermediate for imatinib, which is tyrosine protein kinase inhibitor for treating chronic myeloid leukemia and other diseases, and its analog N- phenyl-pyrimidiyl-2-amine derivative. The target product may be prepared through condensation of 4-aromatic heterocycle-2-halogenated pyrimidine and substituted aniline in the presence of catalyst. The preparation process has low material cost, scientific synthesis path, high product yield and other advantages.

The present invention relates to compounds having the general formula

or a pharmaceutically acceptable salt thereof, wherein R¹ is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, 0 and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R¹ is additionally substituted; and R² is a substituted C_1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

The invention discloses a glycyrrhetinic acid-hydrogen sulfide donor reagent derivative, and a synthetic method and an application thereof. The synthetic method of the derivative comprises the following steps: carrying out a reaction on glycyrrhetinic acid, alpha,omega-dibromoalkane and an alkali in an aprotic polar solvent to obtain a compound 1; and carrying out a reaction on the compound 1, a hydrogen sulfide donor and the alkali in the aprotic polar solvent to obtain a crude target product, wherein the reactions are carried out under heating or non-heating conditions. Most compounds in the synthesized derivative have certain inhibition activity to a chronic marrow leukemia cell K562, and are hopeful to be used in the preparation of corresponding antitumor medicines and chronic marrow leukemia cell treatment medicines. The synthesized derivative has a structure represented by general formula (I) shown in the description; and in the general formula (I), n is 2-8, and R is one of three formulas shown in the description.

Methods for cancer treatment include administering to a cancer patient an anti- CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.

The invention provides small molecule heteroaromatic compounds that are ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency towards resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor resistant diseases, such as imatinib resistant chronic myelogenous leukemia.

The invention discloses spirostanol saponins and application thereof. The spirostanol saponins is extracted and separated from tupistra chinensis rhizomes. The spirostanol saponins and the application have the advantages that as discovered in experimental research, excellent effects can be realized by nine types of spirostanol saponins in the aspects of cancer prevention and anti-inflammation actions, certain suppression effects can be realized by the spirostanol saponins for pharynx squamous cell carcinoma, pharynx cancer, nasopharyngeal squamous cell carcinoma, liver cancer, chronic myelocytic leukemia, lung adenocarcinoma and the like, and accordingly the spirostanol saponins is high in efficiency and low in toxicity and can be hopefully developed to obtain novel anticancer medicines and healthcare foods.

Compounds of formula (I) wherein n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R<1> is 2,4-diCI, 5-OMe; 2,4-diCI; 3,4,5-triOMe; 3-CI, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCI, 5-OEt; R<2> is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof are useful for the treatment of chronic myelogenous leukemia (CML).

The invention provides an application of a drug containing catechin or polymorphic bodies to preparation of a drug for preventing and/or treating leukemia. In vivo experiment research shows that the catechin can significantly inhibit proliferation of related leukemic cells after being orally taken or injected; in vitro experiment research shows that the catechin can inhibit growth of leukemic cells. The catechin has wider treatment range for leukemia and has exact treatment effects on leukemia including lymphocytic leukemia, reticulocyte leukemia, chromic myeloid leukemia and the like. Meanwhile, toxic and side effects are not discovered, so that the drug has prominent promotion prospect.

This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in the treatment of a Rac-GTPase mediated disorder (e.g., acutelymphoblastic or chronic myelogenous leukemia), as well as methods for the manufacture of and the use of these compounds for treating a Rac-GTPase mediated disorder.